Chronic Inflammatory Response Syndrome (CIRS) and the Evidence for Treatment: What a 2024 Review Found
Apr 9 Written By Michele GrayCIRS has become a hot topic for people dealing with persistent symptoms after mold or water‑damage exposure, but it can be hard to sort solid science from marketing. A 2024 peer‑reviewed review in Frontiers in Medicine, archived on PubMed Central, took a close look at the existing evidence on CIRS and its treatments and came to several practical conclusions.
What is CIRS?
The review describes Chronic Inflammatory Response Syndrome (CIRS) as an acquired, multi‑system illness triggered by exposure to biotoxins such as those found in water‑damaged buildings, tick‑borne infections, and certain marine toxins. Rather than behaving like a classic allergy, CIRS involves ongoing activation of the innate immune system, with measurable changes in inflammatory markers and regulatory neuropeptides in susceptible individuals.
Patients with CIRS often report clusters of symptoms affecting multiple systems: fatigue, brain fog, headaches, sinus issues, shortness of breath, temperature dysregulation, and gut problems, among others. Genetic factors, frequently specific HLA types, may help explain why some people become very ill in an environment where others feel fine, although this area still needs more research.
How CIRS is Diagnosed in the Literature
The paper outlines a structured diagnostic framework frequently used in CIRS research, particularly by Dr. Ritchie Shoemaker’s group. It typically includes:
-
A clear exposure history to a known biotoxin source, especially water‑damaged buildings
-
A characteristic, multi‑system symptom pattern
-
Abnormal visual contrast sensitivity (VCS) testing
-
A panel of blood markers such as C4a, TGF‑β1, MMP‑9, VEGF, VIP, and MSH
-
Sometimes HLA genetic testing to assess susceptibility
This framework originates largely from one research group and is not yet part of mainstream medical guidelines, but within that model the authors found consistent patterns: abnormal labs at baseline that move toward normal as patients improve with treatment. That linkage between exposure, objective findings, and clinical response is a central theme of the review.
What the Review Found About Treatment
The authors examined all peer‑reviewed literature they could locate on CIRS and related treatment approaches. Of 13 CIRS treatment papers identified, 11 described the same structured approach commonly known as the Shoemaker Protocol.
Across those studies—which include double‑blind placebo‑controlled trials, case series, cross‑sectional work, and a case–control study—the protocol was associated with:
-
Significant reductions in total symptom scores
-
Improvement or normalization of VCS test results
-
Shifts in inflammatory markers and hormones toward healthier ranges
-
In some work, changes in gene expression and even brain imaging consistent with recovery
On this basis, the review concludes that this protocol is currently the only CIRS treatment with published evidence for clinical efficacy, while many other commonly discussed approaches remain anecdotal or untested in formal trials.
Where Indoor Air Testing Fits In
One of the most practical findings from the review is that ongoing exposure to water‑damaged buildings can block recovery or trigger relapse, even when medical treatment is otherwise on track. That makes accurately identifying and confirming low‑exposure indoor environments a crucial real‑world step for people with CIRS or other biotoxin‑related illnesses.
A real‑time, 11‑parameter indoor air inspection is well‑suited to this task. By capturing multiple dimensions of airborne particles and behavior in each room, this approach can be used to:
-
Screen for elevated bioaerosol loads in water‑damaged or suspect spaces
-
Pinpoint “hot spots” in a home or workplace that may require targeted remediation
-
Re‑check spaces after remediation or moisture control work to document that airborne particle levels have dropped into more typical background ranges
Instead of a single grab sample, you get a room‑by‑room, dynamic view of the air people are actually breathing—data that environmental professionals can use to better characterize the exposure side of the CIRS equation and support clinicians who are matching symptoms and lab findings to real‑world conditions.
Limitations and Why This Matters for Patients
The review is careful about its limitations: most CIRS treatment data come from one investigative group, sample sizes are modest, and there are no large, multi‑center randomized trials yet. The authors call for independent replication, larger studies, and broader validation of both diagnostic criteria and treatment steps.
For patients who have been told “your labs are normal” or “mold can’t cause that,” this paper matters because it:
-
Recognizes CIRS as an inflammatory, biologically measurable illness in at least a subset of chronically ill patients
-
Shows that a structured, evidence‑informed protocol has repeatedly shifted both symptoms and lab markers in the right direction
-
Underscores the importance of addressing the environment—not just prescribing medications—in people sensitive to water‑damaged buildings
When you combine that medical framework with careful building evaluation and modern, real‑time, multi‑parameter airborne testing, you create a more complete path: identify likely exposure, document and correct indoor air problems, and coordinate with CIRS‑aware clinicians so that medical treatment and environmental control move in the same direction. For many people stuck in chronic, unexplained illness after water damage or mold exposure, that integrated approach may be the missing piece that finally connects their symptoms to both the science and their surroundings.
Michele Gray Previous Previous